Abstract 1597P
Background
Cancer is the leading cause of death in Ireland, accounting for 28.5% of all deaths in 2021. Our aging population is predicted to drive a significant increase in new cancer cases in the coming decades. As such, high quality end-of-life care (EOLC) for patients dying in the acute hospital setting is an essential part of delivering holistic care to patients with cancer and their families. This is the second audit cycle to examine the quality of EOLC in one of the largest university teaching hospitals in Ireland. The first audit cycle, during the COVID-19 pandemic, identified several shortcomings in EOLC ( ESMO 2022 : S1134).
Methods
A care of dying patients guidance document, EOLC quality checklist, and staff education huddles facilitated by the Hospital Palliative Care Team were introduced in July 2022. A second retrospective chart review of patients who died under the care of the medical oncology service between 11th July 2022 and 30th April 2023 was performed. Data on the quality of EOLC delivered was collected and assessed using the published Oxford Quality Indicators for mortality review. An overall score for EOLC between 1 (very poor) and 5 (excellent) was assigned to each patient. These were compared with the previously presented 2021 cohort.
Results
We identified 72 patients (41 female). The median age at death was 65 years [23-89]. The mean length of admission resulting in death was 15.2 days [0-118]. The mean quality score for EOLC was 4.0, compared to 3.5 pre-intervention. Exploration of patient wishes, and spiritual care were documented in 45.8% and 58.3% of cases respectively, compared to 24.2% and 10.6% in the initial audit. 42 patients (58.3%) had care of the dying patient documents completed. The mean quality score for EOLC for these patients was 4.6, versus 3.2 for those without the document.
Conclusions
The quality of EOLC in our organisation has improved numerically in the second audit cycle. Areas of ongoing non-compliance to the Oxford Quality Indicators include exploration of patient wishes and spiritual care. The end-of-life committee, which now includes doctors in training, is committed to continuing to address deficits in the quality of EOLC in our institution, as an ESMO Designated Centre of Integrated Oncology and Palliative Care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05